Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
IONIS PHARMACEUTICALS INC executive Frank C. Bennett, EVP and Chief Scientific Officer, reported acquiring 110 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this purchase, he directly holds 60,128 shares of Ionis common stock. The filing states these purchased shares may not be sold until February 28, 2027, and no Rule 10b5-1 trading plan is reported for this transaction.
IONIS PHARMACEUTICALS INC (IONS) reported that executive vice president, chief legal officer and general counsel Patrick R. O'Neil acquired 63 shares of common stock on August 31, 2026 through the company’s employee stock purchase plan at $51.306 per share. Following this purchase, he directly holds 59,205 shares. According to the plan terms described, these 63 shares may not be sold until February 28, 2027, and the filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.
IONIS PHARMACEUTICALS INC (IONS) reports that Chief Executive Officer and director Brett P. Monia acquired 98 shares of common stock on August 31, 2026 through the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this transaction, Monia directly holds 242,760 shares of Ionis common stock. According to the plan terms, these 98 shares may not be sold until February 28, 2027. No Rule 10b5-1 trading plan is reported for this transaction.
IONIS PHARMACEUTICALS INC (IONS) reports that executive vice president Brian Birchler acquired 58 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share.
The footnote states these shares may not be sold until February 28, 2027. Following this transaction, Birchler directly holds 102,883 shares of Ionis common stock.
IONIS PHARMACEUTICALS INC director Michael R. Hayden reported two open-market purchases of common stock by Genworks 2 Consulting, Inc., an entity through which his spouse holds shares with sole voting and investment power. Genworks 2 acquired 15,000 shares on July 30, 2026 at a weighted-average price of $53.38 and 5,000 shares on July 31, 2026 at a weighted-average price of $51.60, for a total of 20,000 additional indirectly held shares. Hayden also reports direct ownership of 54,298 Ionis common shares.
Ionis Pharmaceuticals reported Q2 2026 revenue of $267.9 million, down from $452.0 million a year earlier as prior-year collaboration upfronts did not repeat. Commercial revenue grew 15% to $118.6 million, led by DAWNZERA and early TRYNGOLZA sales. The company posted a net loss of $114.6 million versus prior-year profit of $123.6 million, as operating expenses rose with multiple launches.
For the first half of 2026, revenue was $514.0 million and net loss $207.2 million. Cash and cash equivalents were 350,065 (in thousands) and short-term investments 1,704,520 (in thousands) at June 30. The company repaid $432.5 million of 0% 2026 notes while continuing significant R&D investment. The FDA approved TRYNGOLZA for severe hypertriglyceridemia, while a Phase 3 ATTR‑CM trial of eplontersen missed its primary endpoint. Multiple partners paid milestones contributing approximately $180 million of R&D revenue in the half.
Ionis Pharmaceuticals reported Q2 2026 total revenue of $268 million, down from $452 million a year earlier, as prior-year results included a $280 million upfront payment related to a global license of sapablursen. Commercial revenue grew to $119 million, up from $103 million, driven mainly by DAWNZERA product sales and royalties from SPINRAZA and WAINUA. Product sales reached $31 million, compared with $19 million in Q2 2025.
Operating expenses rose to $370 million from $312 million, reflecting investment in launches for TRYNGOLZA and DAWNZERA and launch preparations for zilganersen. Ionis posted a GAAP net loss of $115 million versus net income of $124 million a year earlier; on a non-GAAP basis, net loss was $70 million versus non-GAAP net income of $154 million. Cash, cash equivalents and short-term investments were $2,055 million at June 30, 2026, down from $2,677 million at December 31, 2025, primarily after repayment of 0% convertible notes.
The company highlighted U.S. approval and early launch momentum for TRYNGOLZA in severe hypertriglyceridemia, DAWNZERA’s growth in hereditary angioedema, completion of enrollment in the Phase 3 REVEAL Angelman syndrome trial, and stated it remains on track to achieve its 2026 financial guidance and a goal of cashflow breakeven in 2028.
Reikes Peter N reported acquisition or exercise transactions in this Form 4 filing.
Ionis Pharmaceuticals Inc granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026 under its Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. The RSUs vest in three equal annual installments starting July 15, 2027 and will be fully vested on July 15, 2029. Following this award, Reikes holds 3,399 RSUs directly, all unvested as of the grant date.
HANTSON LUDWIG reported acquisition or exercise transactions in this Form 4 filing.
Ionis Pharmaceuticals director Ludwig Hantson received a grant of 3,399 Restricted Stock Units on July 15, 2026 under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Each RSU is a contingent right to one share of common stock or its cash value, vesting in three equal annual installments from July 15, 2027 and fully vesting on July 15, 2029. As of the grant date, 0 RSUs were vested and he holds 3,399 RSUs in total.
Ionis Pharmaceuticals director Joan E. Herman reported the vesting of 5,220 Restricted Stock Units on July 15, 2026, which were settled into 5,220 shares of common stock at $0.0000 per share. Following this derivative exercise, she directly holds 51,306 common shares and 2,301 Restricted Stock Units.